Our discovery and development process always begins with the patient.
We ask ourselves these important questions: How are patient needs not
currently being met? How can we improve their treatment options? How
can we work toward better outcomes? Starting with patient needs helps
us focus our efforts and keeps our eye on our goal: to help patients
improve their health and their lives.
Our discovery and development efforts are focused on a core set of
therapeutic areas where we have proven expertise and where we believe
we can have an even greater impact on the disease and how it is
managed. Read more about medicines we’re developing in these areas
in Pipeline.
AbbVie’s Hepatitis C virus (HCV) clinical development program is intended to advance science and medicine by researching innovative treatment options for patients with the goal of curing as many people living with HCV as possible. Hepatitis C continues to be an important public health issue, approximately 250,000 Canadians are chronically infected with HCV(1).
We’re also developing innovative therapies for neurodegenerative diseases for conditions such as Parkinson’s disease; nearly 100,000 Canadians have Parkinson’s disease.
We have been leveraging deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology.
We currently have treatment approved in Canada for Prostate Cancer and relapsed/refractory Chronic Lymphocytic Leukemia. Future areas of focus include leveraging our experience in immunology to develop next-generation immuno-oncology therapies and growing a strong position in hematologic malignancies.
We provide treatments for women suffering from endometriosis and uterine fibroids, which each affect more than 16 million women worldwide. Both are highly prevalent conditions associated with symptoms, including pain and infertility.
We continue to focus on research and development for other disease areas of significant need: